Gynecological

Wednesday, July 13, 2016

Education key to acceptance of surgery step to prevent ovarian cancer


CANCER DIGEST – July 12, 2016 – Ovarian cancer most often starts in the fallopian tubes, an observation that caused the American College of Obstetricians and Gynecologists (ACOG) to issue an opinion in January 2015 recommending that women undergoing hysterectomies for non-cancerous conditions should also have the fallopian tubes removed, while sparing the ovaries as a way to prevent ovarian cancer.

In issuing their opinion, the ACOG acknowledged that randomized controlled clinical trials are needed to determine if salpingectomy, or removing fallopian tubes, does reduce ovarian cancer risk.

Thursday, June 30, 2016

Gene complex predicts ovarian cancer survival


Richard Morgan is the Director of the University of 
Bradford's Institute of Cancer Therapeutics in the UK
Image courtesy of U of Bradford
CANCER DIGEST  – June 29, 2016 – A new British study has identified a genetic marker that predicts poor survival from ovarian cancer. In addition, the study also identified a set of genes that help the cancer develop resistance to chemotherapy.

The study, published in the International Journal of Cancer, examined the role of HOX genes in ovarian cancer resistance to chemotherapy and whether a drug known as HXR9, which targets HOX, could help prevent the resistance from developing.

Thursday, March 31, 2016

Study gives new meaning to having a chemical peel


CANCER DIGEST – March 31, 2016 – A chemical peel may prevent cervical cancer, a new Austrian study shows. Researchers at the Comprehensive Cancer Center (CCC) of MedUni Vienna and Vienna General Hospital have developed a new treatment for the pre-stages of cervical cancer, caused by human papilloma virus (HPV) infection. The study appeared in the Feb. 2016 Obstetrics & Gynecology.

The treatment involves using 85% trichloroacetic acid, an acid that is traditionally used for medical and cosmetic skin peeling. 

Wednesday, January 20, 2016

'Simple Rules' boost ovarian cancer determination


Cancer Research UK / Wikimedia
Commons
CANCER DIGEST – Jan. 20, 2016 – New method of evaluating ovarian lesions shown on ultrasound could dramatically improve the ability of doctors to accurately determine whether they are cysts or cancerous tumors.

In a study published online today in the American Journal of Obstetrics and Gynecology, a group of European researchers led by Professor Dirk Timmerman, MD, PhD, of the Department of Obstetrics and Gynecology, University Hospitals Leuven, Belgium, showed the new method to be accurate nearly 90 to 100 percent of the time, which could speed treatment for those women diagnosed with ovarian cancer.

Wednesday, September 2, 2015

Common heart drug linked to longer survival in ovarian cancer


A very large ovarian cancer (in circle) as seen on CT
CANCER DIGEST – Sept. 2, 2015 – A common drug used to lower blood pressure has been linked to longer survival in women who underwent chemotherapy for ovarian cancer.

The study looked at the records of 1,425 women who had previously been treated for ovarian cancer, including 269 who were also taking a beta-blocker during chemotherapy. The study was published in the journal Cancer.

Monday, April 13, 2015

HPV vaccine for boys could prevent oral cancer, save money


Imagae: courtesy CDC
CANCER DIGEST – April 13, 2015 – The vaccine that prevents cervical cancer in girls may save healthcare dollars if comprehensive vaccination of boys were implemented to prevent oral cancers in boys.

A new study suggests that vaccinating 12-year-old boys against the humanpapilloma virus (HPV) may be a cost-effective strategy for preventing oropharyngeal squamous cell cancer, a cancer that starts at the back of the throat and mouth, and involves the tonsils and base of the tongue.

Monday, November 17, 2014

Anti-leukemia drug may also work against ovarian cancer


Ovarian cancer cells are shown
forming small tumor. Image courtesy
of University of Gothenburg
CANCER DIGEST – Nov. 17, 2014 – An experimental monoclonal antibody called cirmtuzumab is currently in a first-in-human phase 1 clinical trial to assess its safety and effectiveness in treating chronic lymphocytic leukemia CLL may also prove effective against ovarian cancer as well as others, a new study shows.

Developed at UC San Diego Moores Cancer Center by Thomas Kipps, MD, PhD, and colleagues, cirmtuzumab targets a specific protein that is normally inactive in adult normal cells. The new study appears on the Nov. 17 online early edition of the Proceedings of the National Academy of Sciences (PNAS).

Monday, November 10, 2014

New drug shows promise for people with BRCA1 or 2 cancers


CANCER DIGEST – Nov. 10, 2014 – People with certain cancers that stem from mutations of the BRCA1 or BRCA2 gene may soon have another treatment option to slow the cancer progression.

In an early stage clinical trial of the twice-daily drug olaparib, 26 percent of patients had their tumors shrink or disappear for up to 7 months. The phase II trial was designed to determine whether tumors responded to the drug. Whether the drug significantly increases survival will need to be tested in larger phase III studies.

Friday, October 17, 2014


New test may boost accuracy of ovarian cancer diagnosis

Photo courtesy of BMJ – Dr. P. Marazzi
CANCER DIGEST – Oct. 17, 2014 – A new test to help doctors diagnose ovarian tumors and choose the most appropriate treatment is ready for clinical use, researchers say.

In a study published today in the British Medical Journal, an international team led by Imperial College London and KU Leuven, Belgium describe the new test, called ADNEX, which can discriminate between benign and malignant tumors, and identify different types of malignant tumor, with a high level of accuracy.

Wednesday, July 9, 2014

FDA to scrutinize cancer risks of uterine surgical device


YouTube courtesy:Smith & Nephew Digital Communications
CANCER DIGEST – July 9, 2014 – Sale and use of a device used in a minimally invasive surgery to remove uterine fibroids, called myomectomy, and to perform hysterectomies has been suspended pending a FDA advisory committee meeting July 10 and 11. The committee will examine recent cases linking the device to the spread of a rare cancer. The device is a laparoscopic morcellator, which is used to cut fibroid and uterine tissue into small pieces that can be removed through a small incision. The device has been used since the early 1990s to perform more than 50,000 hysterectomies or myomectomies each year. In an alert issued in April, the FDA estimated that 1 in 350 women undergoing such procedures is found to have unsuspected uterine cancer. “If laparoscopic power morcellation is performed in women with unsuspected uterine sarcoma,” the alert stated, “there is a risk that the procedure will spread the cancerous tissue within the abdomen and pelvis, significantly worsening the patient’s likelihood of long-term survival.” Some hospitals have suspended the use of the device and Johnson & Johnson, the largest manufacturer of the device, has halted sales, distribution and promotion of the device until FDA’s investigation is completed and the role of the device in these procedures is redefined.

Sunday, June 22, 2014

New drug shows promise for recurrent ovarian cancer


Garland Science YouTube channel
CANCER DIGEST – June 22, 2014 – Women treated with a new type of drug halted their recurrent ovarian cancer significantly longer than women treated with a standard chemotherapy treatment, according to a new report in the June 19,Lancet Oncology. The doctors at the University of Arizona Cancer Center published data from 919 women with recurrent ovarian cancer treated at 179 cancer centers in 32 countries. The drug, called Trebananib is a first-in-class agent that prevents two proteins from binding to a tumor cell receptor that triggers the process of angiogenesis, or growing blood vessels needed for  tumor growth. Women in the trial who received the drug plus paclitaxel had disease progression halt for an average of 7.2 months compared to 5.4 months for women treated with paclitaxel. Previous anti-angiogenesis drugs, like bevacizumab (Avastin®), block a growth factor (VEGF) needed for blood vessel growth.  

Monday, June 2, 2014

Combination therapy halts disease progression nine months more in recurrent ovarian cancer


Jane Robertson, MD, Global Product Vice 
President for olaparib at AstraZeneca, 
describes the mechanism of action of 
olaparib. YouTube

CANCER DIGEST – June 2, 2014 – Advances in treating recurrent ovarian cancer are usually marked in weeks or a month or two. So a study showing disease progression halted by an additional nine months is capturing attention at this week’s annual meeting of the Association of Clinical Oncologists in Chicago. In a Dana Farber Cancer Cancer Institute study, 90 women with recurrent ovarian cancer received a targeted therapy, called olaparib, or olaparib with another targeted therapy called cediranib. Almost half (48 percent) of those who received the single drug treatment had their tumors shrink and had the cancer held in check for an average of nine months. By comparison 80 percent of those in the combination treatment group had their tumors shrink and it took an average of 18 months before the cancer resumed progression. Targeted therapies act on specific proteins or genes of the tumor resulting in milder side effects than typically occurs with chemotherapy. 

Thursday, April 24, 2014


FDA approves HPV test for cervical cancer screening

FDA NEWS RELEASE – April 24, 2014 – The FDA today expanded its approval of a DNA test as a standalone screen for the strains of virus that cause cervical cancer. The cobas HPV Test had previously been approved as a co-test along with a Pap test as a primary screening test for cervical cancer. The expanded approval was based on research data gathered from more than 40,000 women 25 years and older undergoing routine cervical exams involving either the Pap or HPV test and biopsy. After three years of follow-up, women who went to colposcopy showed that the cobas HPV Test by itself is safe and effective for cervical cancer screening use.   
Read more ...


Tuesday, March 25, 2014

Obesity increases risk of uterine cancer

MEDICAL NEWS TODAY – Mar. 25, 2014 – Obese women reduced their risk of uterine cancer by 71 percent following bariatric surgery that resulted in a dramatic weight loss and 81 percent if normal weight is maintained. Analyzing data from more than 7 million patients compiled by a consortium of university health systems, researchers at the University of California, San Diego found that a woman with a BMI of 40 has approximately eight times greater risk of endometrial cancer compared to women with a BMI of 25. Their findings suggest that bariatric surgery may be useful for heading off endometrial cancer in certain patients. They published the study in the April issue of Gynecologic Oncology
Read more …May 6, 2010 – QUEBEC CITY (Cancer Digest) – Orphan status granted for ovarian cancer drug

May 20, 2010 – HOUSTON (Cancer Digest) – Change in blood protein over time may detect ovarian cancer